CSPC and AstraZeneca form Shijiazhuang biologics venture with 51%-49% split

The planned Hebei manufacturing base would pair CSPC's AI-driven GMP system with AstraZeneca's global quality and supply chain expertise, pending regulatory approvals.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.